NASDAQ:PAA ASX:BRN MIL:BRE ASX:RIM ASX:DRO NYSE:FND GETTEX:STP NASDAQ:BVS ASX:RDM
Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list.
The Launch Pad List is published weekly...
NYSE:ARR MIL:BRE ASX:RIM ASX:BRN ASX:ACW ASX:RDM GETTEX:CXU EURONEXT:CTT NASDAQ:PAA
Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list.
The Launch Pad List is published weekly...
PAA is trading currently n a descending wedge and is struggling to close above long term trendline. If it manages to close in the given spot (Green Circle Buy Zone), then it may confirm a change in trend and may get bullish, as this is a very Bullish structure. We need to see good volume and a thrust to the upside for confidence. Lets see how it develops in the...
Watchlist
Volume drop off after reach 27.5c high
17c seems to be the next key support
Watch if price can stabilise and stay above 21EMA
If price pushes up, will probably see some resistance at 27.5c
after the pump through 19 recently this thing has come back and tested support. Id suggest clearly not being bought up by funds. However, looking much better for a test of resistance on the hourly at 22.5c.
From the recent presentation, the next move was to test their drug against human lung tissue to test its impact on covid infected cells.
This is a biostock so, very high risk play. Been looking/waiting for the move above the May 12 high of 17.5c. Lets see how they close it this week. Their drug appears to be effective in suppressing the covid virus in cell culture. Human safety already achieved, so awaiting phase 1 trials.
PharmAust is a clinical-stage company developing targeted cancer therapeutics for both humans and animals through re-purposing marketed drugs lowering the risks and costs of development. They look to have broken through a previous resistance area and could be worth a watch.
Current demand shows 76 buyers for 3,015,228 units with only 19 sellers for 2,181,188...
